2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
    Neuronal Signaling
  4. Calcium Channel
  5. Calcium Channel Isoform
  6. Calcium Channel Agonist

Calcium Channel Agonist

Calcium Channel Agonists (18):

Cat. No. Product Name Effect Purity
  • HY-103307
    FPL64176
    		Agonist 99.86%
    FPL64176, a nondihydropyridine compound, is a potent agonist of L-type Ca2+ channels with an EC50 value of 16 nM.
  • HY-138119
    γ-Glutamylserine
    		Agonist 98.35%
    γ-Glutamylserine (γ-Glu-Ser) is a calcium receptor activator. γ-Glutamylserine can be used for Parkinson's disease research, as well as diabetes or obesity study.
  • HY-B0106A
    Etiracetam
    		Agonist 99.91%
    Etiracetam (UCB 6474) is an acetylcholine agonist and a nootropic drug of the racetam family. Less active than its S-enantiomer Levetiracetam (UCB L059).
  • HY-P5114A
    Maurocalcine TFA
    		Agonist
    Maurocalcine TFA is an agonist of ryanodine receptor (RyR) channel types 1, 2 and 3 with cellular permeability. Maurocalcine TFA induces [3H]ryanodine binding on RyR1 with an EC50 value of 2558 nM. Maurocalcine TFA exhibits a apparent affinity of 14 nM for RyR2. Maurocalcine TFA can be applied to in vivo cell tracking or other cell imaging techniques.
  • HY-P5114
    Maurocalcine
    		Agonist
    Maurocalcine is an agonist of ryanodine receptor (RyR) channel types 1, 2 and 3 with cellular permeability. Maurocalcine induces [3H]ryanodine binding on RyR1 with an EC50 value of 2558 nM. Maurocalcine exhibits a apparent affinity of 14 nM for RyR2. Maurocalcine can be applied to in vivo cell tracking or other cell imaging techniques.
  • HY-113308AS
    Taurolithocholic acid-d4 sodium
    		Agonist
    Taurolithocholic acid-d4 (sodium) is the deuterium labeled Taurolithocholic acid (sodium salt). Taurolithocholic acid sodium salt, a potent cholestatic agent, is a potent Ca2+ agonist[1].
  • HY-167925
    Rec 15/2615
    		Agonist
    Rec 15/2615 is a potent α(1)-adrenergic agonist that stimulates small cholangiocyte proliferation through the activation of calcium-dependent signaling pathways.
  • HY-113308AS2
    Taurolithocholic acid-d4-1 sodium
    		Agonist
    Taurolithocholic acid-d4-1 (sodium) is the deuterium labeled Taurolithocholic acid. Taurolithocholic acid sodium salt, a potent cholestatic agent, is a potent Ca2+ agonist[1].
  • HY-113308S
    Taurolithocholic acid-d5
    		Agonist
    Taurolithocholic acid-d5 is deuterium labeled Taurolithocholic acid.
  • HY-113308S1
    Taurolithocholic acid-d4
    		Agonist
    Taurolithocholic acid-d4 is deuterium labeled Taurolithocholic acid.
  • HY-B0106AR
    Etiracetam (Standard)
    		Agonist
    Etiracetam (Standard) is the analytical standard of Etiracetam. This product is intended for research and analytical applications. Etiracetam (UCB 6474) is an acetylcholine agonist and a nootropic drug of the racetam family. Less active than its S-enantiomer Levetiracetam (UCB L059).
  • HY-B0106AS
    Etiracetam-d3
    		Agonist
    Etiracetam-d3 is the deuterium labeled Etiracetam. Etiracetam (UCB 6474) is an acetylcholine agonist and a nootropic drug of the racetam family. Less active than its S-enantiomer Levetiracetam (UCB L059)[1].
  • HY-136677
    Lnd 796
    		Agonist
    LND 796 is an aminosteroidal derivative with positive inotropic effects similar to those of digitalis. It exhibits electrophysiological, toxic, and inotropic effects in normal and partially potassium-depolarized ventricular muscles. LND 796 requires higher concentrations than digoxin to induce the same toxic symptoms. It exhibits a concentration-dependent positive inotropic effect on guinea pig papillary muscles in normal potassium solution. In partially potassium-depolarized papillary muscles, LND 796 enhances both components of contraction and increases the amplitude of slow action potentials. The mechanism of positive inotropic action of LND 796 involves enhanced calcium entry in calcium channels and inhibition of sodium-potassium ATPase. Due to its expanded positive inotropic range, LND 796 may have potential application in the treatment of congestive heart failure.
  • HY-126551
    Butenoyl-PAF
    		Agonist
    Butenoyl-PAF is a phospholipid analog of platelet activating factor (PAF-like) that is generated in oxidized low-density lipoprotein (DLDR). Butenoyl-PAF can activate cells that express human PAF receptors, such as neutrophils, monocytes, and platelets, and it stimulates an increase in intracellular calcium ion concentration.
  • HY-113308AS1
    Taurolithocholic Acid-d5 sodium
    		Agonist
    Taurolithocholic Acid-d5 (sodium) is the deuterium labeled Taurolithocholic acid sodium salt. Taurolithocholic acid sodium salt, a potent cholestatic agent, is a potent Ca2+ agonist[1][2].
  • HY-106927
    Bay Y5959
    		Agonist
    Bay Y5959 is a potent calcium channel agonist. Bay Y5959 binds to the DHP receptor in a voltage-dependent manner increases both the mean open time and the mean closed time of the Ca-channel. Bay Y5959 has the potential for the research of congestive heart failure, arrhythmic.
  • HY-137311A
    (S)-Albuterol
    		Agonist
    (S)-Albuterol is a muscarinic receptor and phospholipase C activator. (S)-Albuterol increases intracellular free calcium in airway smooth muscle.
  • HY-120535
    RS 30026
    		Agonist
    RS 30026 is a potent calcium channel agonist with a pEC50 value of 7.45.